Analysts Trim Targets, Still Back Boston Scientific

Overview

• Jim Cramer said on Mad Money that competition has tightened for Boston Scientific, adding the stock could recover but he wants to see it find a bottom first.
• The company’s latest quarter topped revenue and earnings forecasts, yet a lower outlook spooked investors and the shares fell after the report.
• Argus cut its price target to $95 and kept a Buy rating, citing strong positions in cardiovascular, electrophysiology, and neuromodulation and calling the pullback a buying opportunity.
• Truist reduced its price target to $90 while reaffirming a Buy rating, signaling confidence despite softer guidance.
• Wall Street still leans positive with a Strong Buy consensus and broad coverage, even as the stock lags the S&P 500 over the past year and operates through its Cardiovascular and MedSurg device units.